TD Asset Management
CRVS icon

TD Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

TD Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.23M Sell
82,596
-41,142
-33% -$571K ﹤0.01% 1056
2026
Q1 		$1.81M Buy
+123,738
New +$1.97M ﹤0.01% 988
2020
Q1 		– Sell
-13,583
Closed -$74K – 1383
2019
Q4 		$74K Sell
13,583
-29,995
-69% -$105K ﹤0.01% 1384
2019
Q3 		$131K Sell
43,578
-6,000
-12% -$25.2K ﹤0.01% 1318
2019
Q2 		$185K Buy
49,578
+2,200
+5% +$8.62K ﹤0.01% 1301
2019
Q1 		$190K Buy
47,378
+300
+0.6% +$1.27K ﹤0.01% 1311
2018
Q4 		$173K Buy
47,078
+600
+1% +$4.09K ﹤0.01% 1358
2018
Q3 		$399K Buy
46,478
+1,800
+4% +$18K ﹤0.01% 1336
2018
Q2 		$491K Buy
44,678
+400
+0.9% +$4.46K ﹤0.01% 1268
2018
Q1 		$511K Buy
+44,278
New +$419K ﹤0.01% 1195
2017
Q3 		– Sell
-10,744
Closed -$130K – 1306
2017
Q2 		$130K Sell
10,744
-13,305
-55% -$142K ﹤0.01% 1323
2017
Q1 		$499K Buy
24,049
+1,805
+8% +$28.3K ﹤0.01% 1215
2016
Q4 		$318K Sell
22,244
-1,300
-6% -$19.8K ﹤0.01% 1286
2016
Q3 		$387K Buy
+23,544
New +$339K ﹤0.01% 1247

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

TD Asset Management's CRVS Position: Q2 2026 in Review

TD Asset Management reduced its Corvus Pharmaceuticals (CRVS) stake by 33% in Q2 2026, selling an estimated $571K and leaving 82,596 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1056.

TD Asset Management first reported a position in CRVS in Q3 2016 and has held it in 14 quarters since. The position peaked at $1.81M in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • TD Asset Management held 82,596 shares of Corvus Pharmaceuticals worth $1.23M as of Q2 2026.
  • TD Asset Management sold 41,142 Corvus Pharmaceuticals shares in Q2 2026, an estimated $571K.
  • Corvus Pharmaceuticals made up ﹤0.01% of TD Asset Management's portfolio in Q2 2026, its #1056 holding.
  • TD Asset Management first reported a position in Corvus Pharmaceuticals in Q3 2016 and has held it in 14 quarters since.
  • TD Asset Management's Corvus Pharmaceuticals position peaked at $1.81M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.